Halozyme Therapeutics, Inc. (HALO)
NASDAQ: HALO · Real-Time Price · USD
57.75
+0.31 (0.54%)
At close: Feb 21, 2025, 4:00 PM
56.89
-0.86 (-1.49%)
After-hours: Feb 21, 2025, 6:32 PM EST
Halozyme Therapeutics Stock Forecast
Stock Price Forecast
The 9 analysts with 12-month price forecasts for Halozyme Therapeutics stock have an average target of 62.78, with a low estimate of 49 and a high estimate of 75. The average target predicts an increase of 8.71% from the current stock price of 57.75.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Halozyme Therapeutics stock from 9 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Sep '24 | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Buy | 3 | 2 | 2 | 2 | 2 | 2 |
| Hold | 3 | 4 | 4 | 4 | 4 | 4 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 9 | 9 | 9 | 9 | 9 | 9 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Benchmark | Benchmark | Strong Buy Reiterates $75 | Strong Buy | Reiterates | $75 | +29.87% | Feb 20, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $70 → $72 | Strong Buy | Maintains | $70 → $72 | +24.68% | Feb 19, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $70 | Strong Buy | Reiterates | $70 | +21.21% | Feb 4, 2025 |
| Wells Fargo | Wells Fargo | Hold Maintains $62 → $57 | Hold | Maintains | $62 → $57 | -1.30% | Jan 13, 2025 |
| Piper Sandler | Piper Sandler | Hold Maintains $52 → $53 | Hold | Maintains | $52 → $53 | -8.23% | Jan 10, 2025 |
Financial Forecast
Revenue This Year
1.02B
from 829.25M
Increased by 23.48%
Revenue Next Year
1.21B
from 1.02B
Increased by 18.16%
EPS This Year
4.21
from 2.10
Increased by 100.52%
EPS Next Year
5.00
from 4.21
Increased by 18.68%
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 1.1B | 1.3B | 1.6B | |||
| Avg | 1.0B | 1.2B | 1.5B | |||
| Low | 967.3M | 1.1B | 1.4B |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 29.6% | 23.9% | 32.4% | |||
| Avg | 23.5% | 18.2% | 23.6% | |||
| Low | 16.6% | 10.1% | 14.0% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 4.40 | 5.51 | 7.75 | |||
| Avg | 4.21 | 5.00 | 6.48 | |||
| Low | 4.00 | 4.06 | 5.35 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 109.5% | 30.8% | 55.0% | |||
| Avg | 100.5% | 18.7% | 29.7% | |||
| Low | 90.4% | -3.6% | 7.1% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.